



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SM

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/178,840    10/26/98    TRIANTAFYLLOU    A    P/2432-19

002352    IM22/0220  
OSTROLENK FABER GERB & SOFFEN  
1180 AVENUE OF THE AMERICAS  
NEW YORK NY 10036-8403

EXAMINER

SHERRER, C

ART UNIT

PAPER NUMBER

1761

DATE MAILED:

02/20/01

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Interview Summary

Application No.  
09/178,840

Applicant(s)

Triantafyllou

Examiner  
Curtis E. Sherrer

Group Art Unit  
1761

All participants (applicant, applicant's representative, PTO personnel):

(1) Curtis E. Sherrer

(3) Peter McGee

(2) Angeliki Oste Triantafyllou

(4) \_\_\_\_\_

Date of Interview Feb 16, 2001

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☒ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No. If yes, brief description:

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: All claims in general

Identification of prior art discussed:

Lindahl and Papzian


Description of the general nature of what was agreed to if an agreement was reached, or any other comments:  
Applicants will consider amending the claims as found in the attached proposed amendments. Examiner agrees that the amendment, with respect to the "at least one protein degrading enzyme" removes Lindahl from the prior art, both as a 102 or 103 reference. Examiner will research the new claims to see if other art is applicable. Applicants will consider adding the proposed amendments so as to overcome the 112 issues. Will state that the amounts used in the specification, though they are based on weight per volume, are within the claimed ranges (by weight). Will consider providing a reference that teaches the inactivation of recited enzymes to show that the specification inherently possesses the claimed limitation.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.



CURTIS E. SHERRER  
PRIMARY EXAMINER  
ART UNIT 1761

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.